Protalix BioTherapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Protalix BioTherapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00.
- Protalix BioTherapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $3.95M.
- Protalix BioTherapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $2.86M.
- Protalix BioTherapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-12-31 was $0.00.
- Protalix BioTherapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $37.63M, a 673.06% increase from fiscal 2020.
- Protalix BioTherapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $4.87M.
- Protalix BioTherapeutics, Inc. stock issued during period, value, new issues for fiscal 2016 was $6.85M, a 12.24% increase from fiscal 2015.
- Protalix BioTherapeutics, Inc. stock issued during period, value, new issues for fiscal 2015 was $6.10M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2025-06-30 | $3.95M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $2.86M 10-Q · filed 2026-05-13 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $37.63M 10-K · filed 2024-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | |
| 2021-03-31 | $37.63M 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $4.87M 10-K · filed 2021-03-30 | |
| 2016-12-31 | $6.85M 10-K · filed 2019-03-18 | |
| 2015-12-31 | $6.10M 10-K · filed 2018-03-06 | |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $25.39M 10-K · filed 2015-03-12 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $25.39M derived: sum of 4 quarters · filed 2014-03-13 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $25.39M derived: sum of 4 quarters · filed 2014-03-13 |
| 2012-03-31 | $25.39M 10-Q · filed 2013-05-09 | $25.39M derived: sum of 4 quarters · filed 2014-03-13 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $20.59M 10-K · filed 2014-03-13 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | |
| 2011-03-31 | $20.59M 10-Q · filed 2012-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |